Setting A New 52 Week Low, Teligent Inc (Nasdaq:TLGT) Closing Trading At $0.86

TLGT
TLGT

Teligent Inc (Nasdaq:TLGT)

April 16th, 2019

Amidst rising markets Teligent Inc fell ($0.14) Tuesday which equals a 14.12% decline, closing at $0.86. As well as the drop in value, Teligent Inc hit a new 52 week low of $0.82. Teligent Inc bounced 23.17% between low and high. Two technical ‘scores’ for companies to be wary of are the Altman Z1 and the Piotroski2 scores. TLGT scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -0.44, and the Piotroski Score is 2). Despite the drop in value, trading volumes were solid at 223.00% of normal which can indicate investor opportunities.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Financials saw the biggest increase of the day (1.37%), while Real Estate saw the biggest drop (-2.38%). Information Technology has seen the biggest year-to-date gain at 23.78%.

Energy saw the biggest turnaround from its 5-day performance of -1.22%, as it went up 0.64%. Real Estate and Utilities saw turn arounds from their five day positive performance, Real Estate with a drop of -2.38%.

Sector Breakdown

  • Financials went up with a 1.37% change.
  • Energy went up with a 0.64% change.
  • Industrials went up with a 0.59% change.
  • Information Technology went up with a 0.49% change.
  • Consumer Discretionary went up with a 0.48% change.
  • Materials went up with a 0.47% change.
  • Communication Services went up with a 0.21% change.
  • Consumer Staples went down with a -0.06% change.
  • Utilities went down with a -1.39% change.
  • Healthcare went down with a -2.03% change.
  • Real Estate went down with a -2.38% change.

Teligent Inc Info

Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. Its topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Teligent Inc’s score is -0.44) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Teligent Inc’s score is 2), and 9 is the best.

TLGT daily update
TLGT daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.